Lifecura Pharma India Private Limited

• Reduces the risk of heart attack, stroke, and other cardiovascular events in high-risk patients.
• Particularly beneficial for patients with multiple risk factors like diabetes, hypertension, and high cholesterol.

• Prevents recurrent heart attacks and reduces the risk of stent thrombosis after coronary stent placement.

• Rosuvastatin lowers cholesterol levels, improving overall heart health and reducing plaque buildup in arteries.

• Clopidogrel and Aspirin prevent blood clot formation, reducing the risk of clot-related complications like stroke and heart attack.

Additional Information:

• Item Code: 189
• Production Capacity: 50000
• Delivery Time: SAME DAY
• Packaging Details: EACH BOX CONATIN 3 STRIPS EACH STRIP 10 CAPSULES

LMWX 40 mg Injection is a low molecular weight heparin (LMWH) formulation that contains Enoxaparin Sodium (40 mg) as its active ingredient.

It is an anticoagulant (blood thinner) used to prevent and treat the formation of blood clots in veins and arteries.

Generic name: Enoxaparin Sodium

• Used to prevent blood clots in deep veins, especially in:

  • Post-surgery patients (orthopedic, abdominal, or cancer surgery)

  • Bedridden or immobile patients

• Helps prevent pulmonary embolism (PE) — when a clot travels to the lungs.

• Used to treat existing clots and prevent them from growing or traveling.

• Used in patients with:

  • Unstable angina

  • Non-ST elevation myocardial infarction (NSTEMI)

  • ST elevation myocardial infarction (STEMI)
    to reduce the risk of heart attack due to clot formation.

• Helps prevent clotting in the dialysis circuit.

Additional Information:

• Production Capacity: 200000
• Delivery Time: AFTER THE PAYMENT NEXT DAY
• Packaging Details: ROOM TEMPETURE PROCUCTS, EACH CASE CONTAIN 240 PFS

LMWX 60 mg Injection is an anticoagulant (blood thinner) that contains Enoxaparin Sodium 60 mg as its active ingredient.
It belongs to a class of medicines called Low Molecular Weight Heparins (LMWHs) — designed to prevent and treat blood clots.

Generic Name: Enoxaparin Sodium

• Used in patients after major surgeries (orthopedic, abdominal, cancer surgeries).

• Also prescribed to bedridden or immobile patients to prevent clot formation in leg veins.

• Prevents progression to Pulmonary Embolism (PE) — a life-threatening condition caused by clots traveling to the lungs.

• Helps in treating existing blood clots in the veins or lungs.

• Prevents the clot from growing and allows the body to dissolve it naturally over time.

• Used in patients with:

  • Unstable Angina (UA)

  • Non-ST Elevation Myocardial Infarction (NSTEMI)

  • ST Elevation Myocardial Infarction (STEMI)

• Reduces the risk of heart attack by preventing new clot formation in coronary arteries.

• Used to prevent clot formation in dialysis tubing/circuits.

LMWX (Enoxaparin) inhibits two key clotting factors — Factor Xa and Factor IIa (Thrombin).
By doing so, it:

• Prevents new clots from forming

• Stops existing clots from growing

• Allows natural breakdown of clots by the body’s system

Additional Information:

• Production Capacity: 200000
• Delivery Time: AFTER THE PAYMENT NEXT DAY
• Packaging Details: ROOM TEMPETURE PRODUCTS, EACH CASE CONTAIN 240 PCS

Generic Name: Eptifibatide
Strength / Pack: 2 mg/ml × 10 ml vial
Category: Antiplatelet Agent (Glycoprotein IIb/IIIa Receptor Antagonist)

Eptifab (Eptifibatide) is an intravenous antiplatelet medicine that works by inhibiting the platelet glycoprotein IIb/IIIa receptor, preventing platelet aggregation and clot formation. It is mainly used in acute coronary syndrome (ACS) and in patients undergoing percutaneous coronary intervention (PCI/angioplasty).

• Unstable Angina & NSTEMI (Non–ST Elevation Myocardial Infarction)

• Percutaneous Coronary Intervention (PCI) including angioplasty & stenting

• Prevention of thrombotic cardiovascular events in high-risk patients

• Dosage & Administration:

   

  • Administered IV infusion only

  • Initial bolus dose followed by continuous infusion

  • Usual adult dose:

    • Bolus: 180 mcg/kg IV

    • Infusion: 2 mcg/kg/min for up to 72 hours (adjust in renal impairment)

Additional Information:

• Production Capacity: 3000
• Delivery Time: AFTER THE PAYMENT SAME DAY DELIVERY
• Packaging Details: EACH VAIL OF 20GM , 2ML/ML, 10ML

Generic Name: Eptifibatide
Strength / Pack: 0.75 mg/ml × 100 ml vial
Category: Antiplatelet Agent (Glycoprotein IIb/IIIa Receptor Antagonist)

Eptifab is an intravenous antiplatelet medication that selectively blocks the platelet glycoprotein IIb/IIIa receptor, preventing platelet aggregation and thrombus formation. It is primarily used in acute coronary syndrome (ACS) and during percutaneous coronary interventions (PCI).

• Unstable angina & NSTEMI (Non–ST Elevation Myocardial Infarction)

• Percutaneous Coronary Intervention (PCI) including angioplasty & stenting

• Prevention of cardiovascular thrombotic events in high-risk patients

• Dosage & Administration:

   

  • Administered IV infusion only

  • Typical dosing:

    • Initial bolus followed by continuous IV infusion

    • Dose adjusted based on body weight and renal function

  • Usually given under cardiac monitoring in hospital settings

Additional Information:

• Production Capacity: 3000
• Delivery Time: AFTER THE PAYMENT SAME DAY DELIVERY
• Packaging Details: EACH BOX CONATION 100ML VAIL OF EPITIFIBATIDE INJECTION

Cresp 40mg Injection: Overview and Uses
Cresp 40mg Injection contains darbepoetin alfa, a synthetic version of the naturally occurring hormone erythropoietin. It is primarily used to treat anemia (a condition characterized by a low red blood cell count) associated with chronic kidney disease (CKD) and chemotherapy.
Mechanism of Action
Darbepoetin alfa stimulates the bone marrow to produce more red blood cells, thereby increasing hemoglobin levels and improving oxygen delivery throughout the body.
Indications
Cresp 40mg Injection is indicated for:
Anemia due to Chronic Kidney Disease (CKD): Both in patients on dialysis and those not on dialysis.
Anemia due to Chemotherapy: Specifically in patients with non-myeloid malignancies undergoing chemotherapy.

Retelex Kit 18 mg – What It Is & Uses

• Generic name / Composition: Reteplase (18 mg)

• Therapeutic class: Thrombolytic (clot-busting) agent 

• Indication / Use:

  • Used to treat acute myocardial infarction (heart attack) by dissolving blood clots in the coronary arteries. 

  • Restores blood flow to heart tissue and prevents further damage. 

• How It Works: Reteplase activates plasminogen to plasmin, which breaks down fibrin in blood clots. 

• Administration: Given as an intravenous (IV) injection by a healthcare professional. 

• Side Effects:

  • Bleeding risk (major side effect) 

  • Nausea, vomiting, low blood pressure 

  • Bleeding at the injection site 

  • Precautions / Warnings:

    • Not to be self-administered — must be given by trained medical personnel. 

    • Use is contraindicated or very risky in patients with active bleeding, recent surgery, or history of hemorrhagic stroke. 

    • Use with caution in patients with liver or kidney impairment. 

  • Storage: Store below 2° TO 8° C 

  • C. 

Additional Information:

• Production Capacity: 500
• Delivery Time: AFTER THE PAYMENT NEXT DAY
• Packaging Details: COLD CHAIN DRUGS , DESPATCH IN COLD CHAIN BOX WITH ICE PACK